Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT

By afschroeder • December 9, 2025

Armstrong A, Papp KA, Lebwohl M, Savage LJ, Yamanaka K, Vlase DE, Warham R, Lambert J, López Pinto JM, Wixted K, Thaçi D. Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT. Dermatol Ther (Heidelb). 2025 Dec 8. doi: 10.1007/s13555-025-01595-9. Epub ahead of print. PMID: 41359217.

Tags: bimekizumab, biologic therapy, Dermatology, health-related quality of life, IL-17A/F, long-term treatment, patient-reported outcomes, Phase 3 clinical trials, plaque psoriasis, Publications

Quantifying Treatment Burden in Hidradenitis Suppurativa: A Cohort Study

Jeong C, Roberts A, Hur M, Chou P, Katz A, Ma E, Yan MJ, Johnsen N, Nong Y, Armstrong AW. Quantifying Treatment Burden in Hidradenitis[...]

Role of real-world evidence from patient registries for psoriasis in decision-making: a systematic review

Passero L, Simon TA, Zhong Y, Zhuo J, Varga S, Armstrong AW. Role of real-world evidence from patient registries for psoriasis in decision-making: a systematic[...]

Onycholemmal Carcinoma Excised by Mohs Micrographic Surgery With Immediate Frozen Section Bone Examination

Wang J, Patel S, Kolker S, Bennett RG. Onycholemmal Carcinoma Excised by Mohs Micrographic Surgery With Immediate Frozen Section Bone Examination. Dermatol Surg. 2025 Dec[...]